112 related articles for article (PubMed ID: 7741793)
1. [Splenopeptides for climacteric complaints. Comparison of ovarian stimulation with transdermal estradiol substitution].
Lauritzen C; Teucher T; Schmitz H
Arzneimittelforschung; 1995 Mar; 45(3):315-22. PubMed ID: 7741793
[TBL] [Abstract][Full Text] [Related]
2. Efficacy on climacteric symptoms of a new estradiol transdermal patch with active matrix in comparison with a reference reservoir patch. Two long-term randomized multicenter parallel-group studies.
Rovati LC; Schmid K; Giacovelli G; Bonn M; Setnikar I; Wolff F; Genazzani AR
Arzneimittelforschung; 1999 Nov; 49(11):933-43. PubMed ID: 10604047
[TBL] [Abstract][Full Text] [Related]
3. [Transdermal estradiol--the possibility for replacement therapy in the postmenopause].
Rachev E
Akush Ginekol (Sofiia); 1994; 33(3):45-7. PubMed ID: 7793531
[TBL] [Abstract][Full Text] [Related]
4. [Ovarian stimulation by a new therapeutic principle for the treatment of complications of the climacteric. Results of a double-blind crossover study with a defined spleen dialysate].
Möller CP; Lübow H; Schmitz H
Arzneimittelforschung; 1986 Jul; 36(7):1123-9. PubMed ID: 3533088
[TBL] [Abstract][Full Text] [Related]
5. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms.
Van Leusden HA; Albertyn G; Verlaine C; Van Ruymbeke J
Int J Fertil Menopausal Stud; 1993; 38(4):210-8. PubMed ID: 8401679
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of estradiol 1 mg and drospirenone 2 mg in postmenopausal Korean women: a double-blind, randomized, placebo-controlled, multicenter study.
Lee BS; Kang BM; Yoon BK; Choi H; Park HM; Kim JG
Maturitas; 2007 Aug; 57(4):361-9. PubMed ID: 17467203
[TBL] [Abstract][Full Text] [Related]
7. Do different delivery systems of hormone therapy have different effects on psychological symptoms in surgically menopausal women? A randomized controlled trial.
Baksu B; Baksu A; Göker N; Citak S
Maturitas; 2009 Feb; 62(2):140-5. PubMed ID: 19179026
[TBL] [Abstract][Full Text] [Related]
8. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. The Transdermal HRT Investigators Group.
Int J Fertil Menopausal Stud; 1993; 38(1):5-11. PubMed ID: 8485612
[TBL] [Abstract][Full Text] [Related]
9. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
[TBL] [Abstract][Full Text] [Related]
10. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
11. [Transdermal estradiol substitution in the postmenopause, individual dosage adjustment and effectiveness in the treatment of climacteric symptoms].
Schenkel L; von Graffenried A
Schweiz Rundsch Med Prax; 1987 Mar; 76(14):358-61. PubMed ID: 3589291
[No Abstract] [Full Text] [Related]
12. [Clinical experiences with Climen in peri- and postmenopausal women].
Husmann F
Zentralbl Gynakol; 1997; 119(3):123-7. PubMed ID: 9173770
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with transdermal estradiol in the treatment of the climacteric.
Utian WH
Minerva Endocrinol; 1989; 14(1):45-8. PubMed ID: 2543895
[TBL] [Abstract][Full Text] [Related]
14. Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy.
van der Schouw YT; Grobbee DE
Eur Heart J; 2005 Jul; 26(14):1358-61. PubMed ID: 15860515
[TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of lower and standard dosages of transdermal estradiol on serum estradiol levels and vaginal maturation index.
Rungruxsirivorn T; Panyakamlerd K; Trerattanachart S; Taechakraichana N
J Med Assoc Thai; 2006 Sep; 89(9):1362-7. PubMed ID: 17100370
[TBL] [Abstract][Full Text] [Related]
16. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
[TBL] [Abstract][Full Text] [Related]
17. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
18. A randomised study to compare the efficacy and safety of new 17 beta-oestradiol transdermal matrix patch with Estraderm TTS 50 in hysterectomised postmenopausal women. The Lyrelle Study Group.
al-Azzawi F; Van der Mooren MJ; Rolland R; Hirvonen E
Br J Clin Pract; 1997; 51(1):20-3, 25-6. PubMed ID: 9158267
[TBL] [Abstract][Full Text] [Related]
19. Microdose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women.
Bachmann GA; Schaefers M; Uddin A; Utian WH
Menopause; 2009; 16(5):877-82. PubMed ID: 19458560
[TBL] [Abstract][Full Text] [Related]
20. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
